Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Abbott Laboratories Launches Similac 360 Total Care Infant Formula

11/16/2021 | 03:26pm EST


ę MT Newswires 2021
All news about ABBOTT LABORATORIES
01/13ABBOTT LABORATORIES : Ex-dividend day for
FA
01/12Health Care Down On Cyclical Bias -- Health Care Roundup
DJ
01/12Abbott Laboratories Secures FDA Clearance for Ensite Cardiac Mapping Platform
MT
01/12Abbott Labs Gets U.S. Clearance For Heart Mapping Platform
DJ
01/12Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctor..
PR
01/12Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctor..
CI
01/11ABBOTT LABS CEO : Opportunity Exists to do More in Share Buybacks, Looking Closely at M&A ..
MT
01/11Abbott Laboratories Exec Says Expect Covid-19 Testing Demand Strength To Continue In Th..
RE
01/11Abbott laboratories exec says expect covid-19 testing demand strength to continue in th..
RE
01/11Abbott laboratories exec says covid-19 testing will eventually be ramped down but there..
RE
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Financials (USD)
Sales 2021 42 172 M - -
Net income 2021 6 738 M - -
Net Debt 2021 8 198 M - -
P/E ratio 2021 33,8x
Yield 2021 1,33%
Capitalization 220 B 220 B -
EV / Sales 2021 5,41x
EV / Sales 2022 5,57x
Nbr of Employees 109 000
Free-Float -
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 128,16 $
Average target price 142,01 $
Spread / Average Target 10,8%
EPS Revisions
Managers and Directors
Robert B. Ford Chairman, President, Chief Executive Officer & COO
Robert Emmett Funck Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Investment Officer, VP-Business & Technology
Roxanne Schuh Austin Independent Director
Glenn Fletcher Tilton Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABBOTT LABORATORIES-8.94%219 790
MEDTRONIC PLC4.93%145 952
BECTON, DICKINSON AND COMPANY4.43%74 858
HOYA CORPORATION-10.96%49 369
DEXCOM, INC.-16.69%43 357
BAXTER INTERNATIONAL INC.-0.12%42 929